By Mandy Jackson
Daily Journal Staff Writer
Therapies using controversial embryonic stem cells that made paralyzed rats walk in lab tests are one step closer to helping human patients. The developments could spur movement in the marketplace as well.
The U.S. Food and Drug Administration recently approved Menlo Park-based Geron Corp.'s clinical trial of treatments derived from human embryonic stem cells, making it the first ...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In